Dose-limiting toxicity and maximum tolerated dose: still fit for purpose?

Lancet Oncol. 2015 Oct;16(13):1287-8. doi: 10.1016/S1470-2045(15)00248-X.

Authors

Han Hsi Wong¹, Sarah Halford²

Affiliations

¹ Cancer Research UK Centre for Drug Development, Angel Building, London EC1V 4AD, UK; Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Box 193, Cambridge Biomedical Campus, Cambridge CB2 0QQ, UK. Electronic address: han.wong@nhs.net.
² Cancer Research UK Centre for Drug Development, Angel Building, London EC1V 4AD, UK.

PMID: 26433816
DOI: 10.1016/S1470-2045(15)00248-X

No abstract available

MeSH terms

Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / pharmacokinetics
Clinical Trials, Phase I as Topic / methods*
Dose-Response Relationship, Drug
Drug Dosage Calculations
Humans
Maximum Tolerated Dose
Patient Safety
Research Design*
Treatment Outcome

Substances

Antineoplastic Agents